AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade) [Seeking Alpha]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Seeking Alpha
ABBV's Q4 2025 saw 18% Immunology growth and 10% total revenue growth, but Oncology and Aesthetics portfolios declined, highlighting diversification challenges. 2026 adjusted EPS guidance of $14.37–$14.57 excludes unpredictable IPR&D and milestone costs, raising concerns about reliance on M&A for future growth. I downgrade ABBV stock to Hold, as sustaining mid-to-high single-digit growth without heavy acquisitions remains uncertain; growth assumptions drive valuation sensitivity. cagkansayin/iStock via Getty Images When I last assessed AbbVie Inc. ( ABBV ), I was focused on VENCLEXTA, an oncology drug that the company was hoping to expand into myelodysplastic syndrome, or MDS. As it turned out, the Phase 3 registration-enabling VERONA trial flunked, leaving This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wro
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie (NYSE:ABBV) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.MarketBeat
- AbbVie (NYSE:ABBV) was given a new $230.00 price target on by analysts at UBS Group AG.MarketBeat
- AbbVie: The Market Is Getting It Wrong [Seeking Alpha]Seeking Alpha
- AbbVie (NYSE:ABBV) had its price target raised by analysts at Morgan Stanley from $269.00 to $270.00. They now have an "overweight" rating on the stock.MarketBeat
- AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise [Seeking Alpha]Seeking Alpha
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 2/4/26 - Form 8-K
- 1/7/26 - Form 8-K
- 1/5/26 - Form 4
- ABBV's page on the SEC website